title: Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676).
abstract: The anti-CD33 monoclonal antibody linked to NAc-gamma calicheamicin gemtuzumab ozogamicin (CMA-676) was used to treat a patient with Philadelphia/bcr-abl-positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real-time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3-log tumour mass reduction in bone marrow.
authors.affiliation: Department of Haematology, University Hospital Rotterdam, The Netherlands.
authors.forename: M P
authors.initials: MP
authors.lastname: de Vetten
authors.forename: J H
authors.initials: JH
authors.lastname: Jansen
authors.forename: B A
authors.initials: BA
authors.lastname: van der Reijden
authors.forename: M S
authors.initials: MS
authors.lastname: Berger
authors.forename: J M
authors.initials: JM
authors.lastname: Zijlmans
authors.forename: B
authors.initials: B
authors.lastname: Löwenberg
mesh_terms: D000208:Acute Disease; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001853:Bone Marrow / Q000473:pathology; D020732:Cytogenetic Analysis; D005260:Female; D016044:Fusion Proteins, bcr-abl; D000079982:Gemtuzumab; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D010677:Philadelphia Chromosome; D016133:Polymerase Chain Reaction; D012074:Remission Induction
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000922:Immunotoxins; D000079982:Gemtuzumab; D016044:Fusion Proteins, bcr-abl